Partnering opportunity

Italian University is offering the construction of stable mammalian cell lines hyper-producing recombinant proteins to pharmaceutical companies, universities and research centres

Summary

Biology and biotechnology department of an Italian University developed an efficient system to produce recombinant proteins in mammalian cells in culture to be used as drugs or for structural biology studies. The company is looking for pharmaceutical companies, universities and research centers, under a technical cooperation and service agreement.

Partner sought

Big companies, small and medium enterprises active in the pharmaceutical sector developing biosimilar drugs or any other product for whom recombinant protein are needed both in EU and extra EU. University and research centres developing structural biology studies needing recombinant proteins in mammalian cells. The types of partnership considered technical agreement, in order to explore innovative application and research and development solution on recombinant protein and service agreement addressed to pharma company.

Description

Italian university department of biology and biotechnology is offering the construction of cell lines for the production of recombinant proteins in mammalian cells to be used for structural biology studies. Recombinant proteins are particularly relevant in various fields, from drug production and diagnosis to basic research. The expiration of patents for therapeutic protein drugs opens up opportunities for biosimilars to enter the market since pharmaceutical companies are willing to obtain their own expression systems. The production in mammalian cells, although expensive, is necessary for many proteins whose function is dependent on post-translational modifications. We developed a mammalian vector-host cell system which allows high production efficiency, thereby decreasing production costs. We offer to the market the construction of stable mammalian cell lines (human or hamster) constitutively expressing any protein of interest. The system is already working very well and has been used successfully for the construction of human and Chinese hamster cell lines hyper-expressing different proteins such as hydroxylase 3 (LH3) and human erythropoietin. The service includes protein characterization though mass spectrometry (MALDI - TOF/TOF), western blotting, quantitative analysis of RNA by RT-PCR, cellular characterization by fluorescent in situ hybridization (FISH) and several additional molecular and cellular biology methods. The company is looking for international partners such as companies, active in the pharmaceutical field, universities and research centers. The types of partnership considered are technical agreement, in order to explore innovative application and research and development solution on recombinant protein and service agreement addressed to pharma companies needing recombinant proteins in mammalian cells in culture to produce specific drugs.

Advantages and innovations

Through this system the university can deliver cell lines producing high-quality recombinant proteins for industrial applications (production of protein-based drugs, development of new drugs) and for basic research (structural and biochemical studies on human proteins). In particular, their system can be used to produce “biosimilar drugs”, that gained great interest after the expiration of important international patents. The activity includes protein characterization though mass spectrometry (MALDI - TOF/TOF), western blotting, quantitative analysis of RNA by RT-PCR and cellular characterization by fluorescent in situ hybridization (FISH). Main advantages: - Production of recombinant proteins in mammalian cell in culture. The use of mammalian cells is essential for proteins whose functionality relies on post-translational modifications. - Production of higher concentrations of recombinant proteins (up to 200 mg per liter) compared to traditional methods, allowing experiments needing high protein amounts such as crystallography. - Construction of stable cells line, which can be used in several experiments and for long term protein production. In principle any protein, that is not toxic for mammalian cells, can be produced at high yields. - The system allows reduction of costs through the production of high protein yields and can also include protein and cell line characterization.

Development stage

Already on the market

Intellectual Property Rights (IPR)

Other


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company